RTP Mobile Logo
Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Colorectal and Gastroesophageal Cancers (Faculty Presentations)
Released September 2021

Featuring slide presentations and related discussion from Drs Chloe E Atreya, Dustin Deming, Eric Van Cutsem and Zev Wainberg. Published September 7, 2021. (Faculty Presentations)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.


    • Develop a long-term care plan for patients diagnosed with metastatic colorectal cancer (CRC), considering biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
    • Evaluate recently presented clinical research findings applicable to the optimal selection and sequencing of systemic therapy for patients with advanced CRC or gastric/gastroesophageal cancer, and consider how these data sets affect current clinical decision-making.
    • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy for gastric, esophageal or gastroesophageal junction (GEJ) cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
    • Appraise the role of immunotherapy for advanced CRC, and identify patients who may be appropriate for this therapy.
    • Recognize the recent FDA approval of trastuzumab deruxtecan for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen.
    • Assess published research data documenting the efficacy of combined BRAF/MEK/EGFR inhibition for patients with relapsed/refractory CRC and a BRAF V600E mutation to optimally incorporate this therapeutic strategy into clinical algorithms.
    • Evaluate the utility of HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences in the selection and sequencing of systemic therapy for locally advanced or metastatic gastric, GEJ, esophageal and colorectal cancer.
    • Consider available and emerging data with novel agents currently being investigated for gastrointestinal cancers, and refer eligible patients for clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOCRCGEJ21/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Chloe E Atreya, MD, PhD
    Associate Professor in Residence
    Gastrointestinal Oncology Program
    University of California, San Francisco
    Hellen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pionyr Immunotherapeutics; Research Funding (Institution): Bristol-Myers Squibb Company, Gossamer Bio, Guardant Health, Kura Oncology, Merck, Novartis.

    Dustin Deming, MD
    ACI/Schwenn Family Associate Professor
    University of Wisconsin
    School of Medicine and Public Health
    Madison, Wisconsin

    Advisory Committee: Acrotech Biopharma, Bayer HealthCare Pharmaceuticals, MEI Pharma Inc, Pfizer Inc, Promega Corporation; Contracted Research: Arcus Biosciences, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospitals Leuven
    Leuven, Belgium

    Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Pierre Fabre, Roche Laboratories Inc, Servier, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier.

    Zev Wainberg, MD, MSc
    Co-Director GI Oncology Program
    Director of Early Phase Clinical Research
    Jonsson Comprehensive Cancer Center, UCLA School of Medicine
    Los Angeles, California

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Lilly, Merck and Taiho Oncology Inc.

    Release date: September 2021
    Expiration date: September 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):